{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T03:48:01Z","timestamp":1790740081131,"version":"4.1.0"},"reference-count":109,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T00:00:00Z","timestamp":1682640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Nodal T-follicular helper cell lymphoma (T-FHCL) derived from T-follicular helper (Tfh) cell falls into a heterogeneous category of peripheral T-cell lymphoma (PTCL). Due to the limited number of therapeutic regimens and limited first-line efficacy, T-FHCL has a poor prognosis, and there is an urgent need for effective targeted therapies. With advancements in sequencing technologies, especially single-cell sequencing and next-generation sequencing, more specific genetic aberrations characteristic of T-FHCL can be discovered, allowing for precise molecular diagnosis and specific research on novel agents. Many biomarker-targeting agents, used either alone or in combination, have been tested, and they have generally enhanced the therapeutic outcomes of T-FHCL. Histone deacetylase inhibitors achieve significant clinical benefits in the treatment of T-FHCL, especially in combination therapy. Chimeric antigen receptor T-cell (CAR-T-cell) immunotherapies, hematopoietic stem cell transplantation, and other potential agents merit further study.<\/jats:p>","DOI":"10.3389\/fonc.2023.1163190","type":"journal-article","created":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T05:51:33Z","timestamp":1682661093000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Precise diagnosis and targeted therapy of nodal T-follicular helper cell lymphoma (T-FHCL)"],"prefix":"10.3389","volume":"13","author":[{"given":"Jun","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shikai","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghui","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingwen","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenwei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoufang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weisong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Hou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,4,28]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-020-00889-z","article-title":"Biomarker-driven management strategies for peripheral T cell lymphoma","volume":"13","author":"Mulvey","year":"2020","journal-title":"J Hematol Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2011.1.515","article-title":"Therapies for peripheral T-cell lymphomas","volume":"2011","author":"Savage","year":"2011","journal-title":"Hematology"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-019-03694-y","article-title":"First-line therapy for T cell lymphomas: a retrospective population-based analysis of 906 T cell lymphoma patients","volume":"98","author":"Janikova","year":"2019","journal-title":"Ann Hematol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31861","article-title":"The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: report from COMPLETE, a prospective, multicenter cohort study","volume":"125","author":"Park","year":"2019","journal-title":"Cancer"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01310-3","article-title":"Management of peripheral T-cell lymphomas and the role of transplant","volume":"24","author":"Foley","year":"2022","journal-title":"Curr Oncol Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.anndiagpath.2018.09.011","article-title":"Diagnostically relevant updates to the 2017 WHO classification of lymphoid neoplasms","volume":"37","author":"Choi","year":"2018","journal-title":"Ann Diagn Pathol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1053\/j.semdp.2019.12.005","article-title":"Update on peripheral T-cell lymphomas with T-helper phenotype: are there too many subtypes","volume":"37","author":"Piris","year":"2020","journal-title":"Semin Diagn Pathol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-021-00937-0","article-title":"Genetic profiling and biomarkers in peripheral T-cell lymphomas: current role in the diagnostic work-up","volume":"35","author":"Vega","year":"2022","journal-title":"Modern Pathol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqaa249","article-title":"Markers of follicular helper T cells are occasionally expressed in T-cell or histiocyte-rich Large b-cell lymphoma, classic Hodgkin lymphoma, and atypical paracortical HyperplasiaA diagnostic pitfall for T-cell lymphomas of T follicular helper origin","volume":"156","author":"Abukhiran","year":"2021","journal-title":"Am J Clin Pathol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.4103\/jcrt.JCRT_486_19","article-title":"Follicular T-cell lymphoma","volume":"17","author":"Lisa","year":"2021","journal-title":"J Cancer Res Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1309\/ajcpbpnv86vzengv","article-title":"Clinicopathologic analysis of peripheral T-cell lymphoma, follicular variant, and comparison with angioimmunoblastic T-cell lymphoma: bcl-6 expression might affect progression between these disorders","volume":"137","author":"Miyoshi","year":"2012","journal-title":"Am J Clin Pathol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1111\/ijlh.12817","article-title":"The 2017 WHO update on mature T- and natural killer (NK) cell neoplasms","volume":"40","author":"Matutes","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"B14","article-title":"Update on recurrent mutations in angioimmunoblastic T-cell lymphoma","volume":"14","author":"Yu","year":"2021","journal-title":"Int J Clin Exp Pathol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.mpdhp.2018.05.006","article-title":"Nodal T-cell lymphomas with a T-follicular helper cell phenotype","volume":"24","author":"Attygalle","year":"2018","journal-title":"Diagn Histopathology"},{"key":"B16","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1111\/bjh.16428","article-title":"The new biology of PTCL-NOS and AITL: current status and future clinical impact","volume":"189","author":"Timmins","year":"2020","journal-title":"Br J Haematol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13393","article-title":"Review of the biologic and clinical significance of genetic mutations in angioimmunoblastic T-cell lymphoma","volume":"109","author":"Fukumoto","year":"2018","journal-title":"Cancer Sci"},{"key":"B18","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/leu.2017.273","article-title":"Activation of RHOA\u2013VAV1 signaling in angioimmunoblastic T-cell lymphoma","volume":"32","author":"Fujisawa","year":"2018","journal-title":"Leukemia"},{"key":"B19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1053\/j.seminhematol.2021.03.001","article-title":"Management of angioimmunoblastic T-cell lymphoma (AITL) and other T follicular helper cell lymphomas (TFH PTCL)","volume":"58","author":"Ma","year":"2021","journal-title":"Semin Hematol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2559.2011.03981.x","article-title":"Peripheral T cell lymphomas with follicular T helper phenotype: a new basket or a distinct entity? revising Karl lennert's personal archive","volume":"59","author":"Agostinelli","year":"2011","journal-title":"Histopathology"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1002\/jlb.5mr1020-057rr","article-title":"Follicular helper T cells and follicular regulatory T cells in the immunopathology of primary sj\u00f6gren's syndrome","volume":"109","author":"Chen","year":"2021","journal-title":"J Leukocyte Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular helper CD4 T cells (TFH)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02918","article-title":"T Follicular helper cell subsets and the associated cytokine IL-21 in the pathogenesis and therapy of asthma","volume":"10","author":"Gong","year":"2019","journal-title":"Front Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1093\/intimm\/dxv079","article-title":"T Follicular helper cells, T follicular regulatory cells and autoimmunity","volume":"28","author":"Zhu","year":"2016","journal-title":"Int Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2008.05.009","article-title":"Generation of T follicular helper cells is mediated by interleukin-21 but independent of T helper 1, 2, or 17 cell lineages","volume":"29","author":"Nurieva","year":"2008","journal-title":"Immunity"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20091738","article-title":"IL-21 acts directly on b cells to regulate bcl-6 expression and germinal center responses","volume":"207","author":"Linterman","year":"2010","journal-title":"J Exp Med"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0904023","article-title":"In vivo Regulation of Bcl6 and T follicular helper cell development","volume":"185","author":"Poholek","year":"2010","journal-title":"J Immunol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/ni.1837","article-title":"Effectors and memories: bcl-6 and blimp-1 in T and b lymphocyte differentiation","volume":"11","author":"Crotty","year":"2010","journal-title":"Nat Immunol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.179.8.5099","article-title":"Role of CXCR5 and CCR7 in follicular Th cell positioning and appearance of a programmed cell death gene-1high germinal center-associated subpopulation","volume":"179","author":"Haynes","year":"2007","journal-title":"J Immunol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1126\/science.1175870","article-title":"Bcl6 and blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation","volume":"325","author":"Johnston","year":"2009","journal-title":"Science"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20090303","article-title":"T Follicular helper cells differentiate from Th2 cells in response to helminth antigens","volume":"206","author":"Glatman Zaretsky","year":"2009","journal-title":"J Exp Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2020.112753","article-title":"T Follicular helper and T follicular regulatory cells in colorectal cancer: a complex interplay","volume":"480","author":"Hetta","year":"2020","journal-title":"J Immunol Methods"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.163.6.3194","article-title":"CD40-CD40 ligand costimulation is required for generating antiviral CD4 T cell responses but is dispensable for CD8 T cell responses","volume":"163","author":"Whitmire","year":"1999","journal-title":"J Immunol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s13148-020-00962-x","article-title":"Epigenetic alterations and advancement of treatment in peripheral T-cell lymphoma","volume":"12","author":"Zhang","year":"2020","journal-title":"Clin Epigenet"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(20)30207-6","article-title":"The peripheral T-cell lymphomas: an unusual path to cure","volume":"7","author":"Ma","year":"2020","journal-title":"Lancet Haematol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/nature25434","article-title":"Tet2 promotes pathogen infection-induced myelopoiesis through mRNA oxidation","volume":"554","author":"Shen","year":"2018","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.ccell.2018.01.001","article-title":"RHOA G17V induces T follicular helper cell specification and promotes lymphomagenesis","volume":"33","author":"Cortes","year":"2018","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2021.03.002","article-title":"Clinicopathological implications of RHOA mutations in angioimmunoblastic T-cell lymphoma: a meta-analysis: RHOA mutations in AITL","volume":"21","author":"Nguyen","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B39","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40164-021-00224-3","article-title":"Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas","volume":"10","author":"Yoon","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/s41392-021-00823-w","article-title":"T Cell receptor (TCR) signaling in health and disease","volume":"6","author":"Shah","year":"2021","journal-title":"Signal Transduction Targeted Ther"},{"key":"B41","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.humpath.2021.07.012","article-title":"Incidence and clinicopathological features of follicular T-cell lymphoma in Finland: a population-based immunohistochemical study","volume":"117","author":"Kiiskil\u00e4","year":"2021","journal-title":"Hum Pathol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/s43018-020-00161-w","article-title":"FYN-TRAF3IP2 induces NF-\u03baB signaling-driven peripheral T cell lymphoma","volume":"2","author":"Moon","year":"2021","journal-title":"Nat Cancer"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1080\/21541248.2016.1263718","article-title":"Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas","volume":"10","author":"Boddicker","year":"2019","journal-title":"Small GTPases"},{"key":"B44","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2020-136465","article-title":"A phase I study of anti-ICOS antibody MEDI-570 for Relapsed\/Refractory (R\/R) peripheral T-cell lymphoma (PTCL) and angioimmunoblastic T-cell lymphoma (AITL) (NCI-9930)","volume":"136","author":"Chavez","year":"2020","journal-title":"Blood"},{"key":"B45","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1016\/j.clml.2019.03.022","article-title":"Phase II study of the PD-1 inhibitor pembrolizumab for the treatment of relapsed or refractory mature T-cell lymphoma","volume":"19","author":"Barta","year":"2019","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-143252","article-title":"A phase II study of pembrolizumab in combination with romidepsin demonstrates durable responses in relapsed or refractory T-cell lymphoma (TCL)","volume":"136","author":"Iyer","year":"2020","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-126194","article-title":"A phase II study of nivolumab in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"134","author":"Bennani","year":"2019","journal-title":"Blood"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-12-542142","article-title":"Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin","volume":"123","author":"Horwitz","year":"2014","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.54.2456","article-title":"Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study","volume":"32","author":"Fanale","year":"2014","journal-title":"J Clin Oncol"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-0838-5","article-title":"Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B\/ACT-2 trial","volume":"35","author":"Wulf","year":"2021","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2013.52.0924","article-title":"Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CC chemokine receptor 4 antibody, in patients with relapsed peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"32","author":"Ogura","year":"2014","journal-title":"J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146977","article-title":"European Phase II study of mogamulizumab, an anti-CCR4 monoclonal antibody, in relapsed\/refractory peripheral T-cell lymphoma","volume":"101","author":"Zinzani","year":"2016","journal-title":"Haematologica"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00103-4","article-title":"Camidanlumab tesirine in patients with relapsed or refractory lymphoma: a phase 1, open-label, multicentre, dose-escalation, dose-expansion study","volume":"8","author":"Hamadani","year":"2021","journal-title":"Lancet Haematology"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-08-802470","article-title":"Activity of the PI3K-\u03b4,\u03b3 inhibitor duvelisib in a phase 1 trial and preclinical models of T-cell lymphoma","volume":"131","author":"Horwitz","year":"2018","journal-title":"Blood"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-140412","article-title":"Duvelisib in patients with Relapsed\/Refractory peripheral T-cell lymphoma from the phase 2 primo trial: dose optimization efficacy update and expansion phase initial results","volume":"136","author":"Pro","year":"2020","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.819.819","article-title":"In Vitro, In Vivo, And parallel phase I evidence support the safety and activity of duvelisib, a PI3K-\u03b4,\u03b3 inhibitor, in combination with romidepsin or bortezomib in Relapsed\/Refractory T-cell lymphoma","volume":"130","author":"Moskowitz","year":"2017","journal-title":"Blood"},{"key":"B57","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.3390\/cancers12082293","article-title":"Phase I\/Ib study of tenalisib (RP6530), a dual PI3K \u03b4\/\u03b3 inhibitor in patients with Relapsed\/Refractory T-cell lymphoma","volume":"12","author":"Huen","year":"2020","journal-title":"Cancers"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx289","article-title":"Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma","volume":"28","author":"Dreyling","year":"2017","journal-title":"Ann Oncol"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.12.009","article-title":"Combination treatment of copanlisib and gemcitabine in relapsed\/refractory PTCL (COSMOS): an open-label phase I\/II trial","volume":"32","author":"Yhim","year":"2021","journal-title":"Ann Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-629543","article-title":"The mTORC1 inhibitor everolimus has antitumor activity in vitro and produces tumor responses in patients with relapsed T-cell lymphoma","volume":"126","author":"Witzig","year":"2015","journal-title":"Blood"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv624","article-title":"A phase II study of everolimus (RAD001), an mTOR inhibitor plus CHOP for newly diagnosed peripheral T-cell lymphomas","volume":"27","author":"Kim","year":"2016","journal-title":"Ann Oncol"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021013379","article-title":"A phase 2 biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK\/STAT targeting in T-cell lymphomas","volume":"138","author":"Moskowitz","year":"2021","journal-title":"Blood"},{"key":"B63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1182\/blood-2020-134650","article-title":"A phase I\/II study (JACKPOT8) of DZD4205, a selective JAK1 inhibitor, in refractory or relapsed peripheral T- cell lymphoma","volume":"136","author":"Kim","year":"2020","journal-title":"Blood"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123986","article-title":"A phase 2 study of the dual SYK\/JAK inhibitor cerdulatinib demonstrates good tolerability and clinical response in Relapsed\/Refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma","volume":"134","author":"Horwitz","year":"2019","journal-title":"Blood"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148352","article-title":"Phase 2a study of the dual SYK\/JAK inhibitor cerdulatinib (ALXN2075) as monotherapy in patients with Relapsed\/Refractory peripheral T-cell lymphoma","volume":"138","author":"Horwitz","year":"2021","journal-title":"Blood"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.60.6327","article-title":"Phase II intergroup trial of alisertib in relapsed and refractory peripheral T-cell lymphoma and transformed mycosis fungoides: SWOG 1108","volume":"33","author":"Barr","year":"2015","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.00899","article-title":"Randomized phase III study of alisertib or investigator\u2019s choice (Selected single agent) in patients with relapsed or refractory peripheral T-cell lymphoma","volume":"37","author":"O\u2019Connor","year":"2019","journal-title":"J Clin Oncol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.Can-19-2787","article-title":"Dasatinib is an effective treatment for angioimmunoblastic T-cell lymphoma","volume":"80","author":"Nguyen","year":"2020","journal-title":"Cancer Res"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2286-1","article-title":"Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I\/II and pharmacokinetics study","volume":"106","author":"Maruyama","year":"2017","journal-title":"Int J Hematol"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1200\/jco.21.01815","article-title":"Romidepsin plus CHOP versus CHOP in patients with previously untreated peripheral T-cell lymphoma: results of the ro-CHOP phase III study (Conducted by LYSA)","volume":"40","author":"Bachy","year":"2022","journal-title":"J Clin Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2014.59.2782","article-title":"Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: results of the pivotal phase II BELIEF (CLN-19) study","volume":"33","author":"O'Connor","year":"2015","journal-title":"J Clin Oncol"},{"key":"B72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40164-021-00203-8","article-title":"Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma","volume":"10","author":"Johnston","year":"2021","journal-title":"Exp Hematol Oncol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv237","article-title":"Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma","volume":"26","author":"Shi","year":"2015","journal-title":"Ann Oncol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.21147\/j.issn.1000-9604.2021.05.08","article-title":"Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma","volume":"33","author":"Gui","year":"2021","journal-title":"Chin J Cancer Res"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26499","article-title":"Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: a multicenter phase II trial","volume":"97","author":"Wang","year":"2022","journal-title":"Am J Hematol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12326","article-title":"Phase I study of vorinostat in combination with standard CHOP in patients with newly diagnosed peripheral T-cell lymphoma","volume":"162","author":"Oki","year":"2013","journal-title":"Br J Haematology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-04-840538","article-title":"Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma","volume":"132","author":"Lemonnier","year":"2018","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009004","article-title":"Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study","volume":"137","author":"Falchi","year":"2021","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01571-8","article-title":"Integrated clinical and genomic evaluation of guadecitabine (SGI-110) in peripheral T-cell lymphoma","volume":"36","author":"Wong","year":"2022","journal-title":"Leukemia"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V130.Suppl_1.4070.4070","article-title":"First-in-Human study of the EZH1\/2 dual inhibitor DS-3201b in patients with relapsed or refractory non-Hodgkin lymphomas \u2014 preliminary results","volume":"130","author":"Maruyama","year":"2017","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129559","article-title":"Safety and anti-tumor activity of CD5 CAR T-cells in patients with Relapsed\/Refractory T-cell malignancies","volume":"134","author":"Hill","year":"2019","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014498","article-title":"Naturally selected CD7 CAR-T therapy without genetic manipulations for T-ALL\/LBL: first-in-human phase I clinical trial","volume":"140","author":"Lu","year":"2022","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003081","article-title":"Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma","volume":"5","author":"Lemonnier","year":"2021","journal-title":"Blood Adv"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-114110","article-title":"Phase I\/II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma: phase II results","volume":"132","author":"Lunning","year":"2018","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-014-2009-0","article-title":"Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed\/refractory peripheral T cell lymphoma (PTCL): report of a phase I\/II trial","volume":"93","author":"Hopfinger","year":"2014","journal-title":"Ann Hematol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1111\/cas.14704","article-title":"Multicenter, dose-escalation study of avadomide in adult Japanese patients with advanced malignancies","volume":"112","author":"Hatake","year":"2021","journal-title":"Cancer Sci"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1111\/cas.13340","article-title":"Phase I\/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma","volume":"108","author":"Maruyama","year":"2017","journal-title":"Cancer Sci"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-019-00630-y","article-title":"Pralatrexate in Chinese patients with relapsed or refractory peripheral T-cell lymphoma: a single-arm, multicenter study","volume":"14","author":"Hong","year":"2019","journal-title":"Targeted Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-018-3418-2","article-title":"Multicenter phase 1\/2 study of forodesine in patients with relapsed peripheral T cell lymphoma","volume":"98","author":"Maruyama","year":"2019","journal-title":"Ann Hematol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128513","article-title":"Proof of concept for tipifarnib in relapsed or refractory angioimmunoblastic T-cell lymphoma (AITL) and CXCL12+ peripheral T-cell lymphoma (PTCL): preliminary results from an open-label, phase 2 study","volume":"134","author":"Witzig","year":"2019","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.789891","article-title":"Venetoclax shows low therapeutic activity in BCL2-positive Relapsed\/Refractory peripheral T-cell lymphoma: a phase 2 study of the fondazione italiana linfomi","volume":"11","author":"Ballotta","year":"2021","journal-title":"Front Oncol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.251454","article-title":"Phase I study of selinexor in combination with dexamethasone, ifosfamide, carboplatin, etoposide chemotherapy in patients with relapsed or refractory peripheral T-cell or naturalkiller\/T-cell lymphoma","volume":"106","author":"Tang","year":"2020","journal-title":"Haematologica"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-0715","article-title":"Phase 1 trial of ALRN-6924, a dual inhibitor of MDMX and MDM2, in patients with solid tumors and lymphomas bearing wild-type TP53","volume":"27","author":"Saleh","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B95","volume-title":"PI3K\/Akt\/mTOR pathway: a growth and proliferation pathway","author":"Cho","year":"2009"},{"key":"B96","doi-asserted-by":"publisher","first-page":"75","DOI":"10.3109\/10799899909036638","article-title":"The jak-STAT pathway: cytokine signalling from the receptor to the nucleus","volume":"19","author":"Heim","year":"1999","journal-title":"J Recept Signal Transduct Res"},{"key":"B97","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1038\/s41571-019-0190-8","article-title":"Emerging epigenetic-modulating therapies in lymphoma","volume":"16","author":"Sermer","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2014.04.004","article-title":"Histone deacetylase inhibitor (HDACI) mechanisms of action: emerging insights","volume":"143","author":"Bose","year":"2014","journal-title":"Pharmacol Ther"},{"key":"B99","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11864-020-00765-5","article-title":"Treatment of relapsed acute myeloid leukemia","volume":"21","author":"Thol","year":"2020","journal-title":"Curr Treat Options Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1038\/s41417-021-00295-8","article-title":"A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb","volume":"29","author":"Wu","year":"2022","journal-title":"Cancer Gene Ther"},{"key":"B101","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1186\/s13287-021-02595-0","article-title":"CAR-T cell therapy in T-cell malignancies: is success a low-hanging fruit","volume":"12","author":"Safarzadeh Kozani","year":"2021","journal-title":"Stem Cell Res Ther"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1007\/s11596-019-2118-z","article-title":"CAR T cell therapy for hematological malignancies","volume":"39","author":"Yang","year":"2019","journal-title":"Curr Med Sci"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1765232","article-title":"Efficacy and safety of single-agent pralatrexate for treatment of angioimmunoblastic T-cell lymphoma after failure of first line therapy: a pooled analysis","volume":"61","author":"Zhu","year":"2020","journal-title":"Leukemia Lymphoma"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2020.1827241","article-title":"Pralatrexate in relapsed\/refractory T-cell lymphoma: a retrospective multicenter study","volume":"62","author":"Bhurani","year":"2021","journal-title":"Leukemia Lymphoma"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.2147\/ott.s140756","article-title":"Forodesine in the treatment of relapsed\/refractory peripheral T-cell lymphoma: an evidence-based review","volume":"11","author":"Makita","year":"2018","journal-title":"OncoTargets Ther"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25655","article-title":"Farnesyl transferase inhibitor treatment of breast cancer cells leads to altered RhoA and RhoC GTPase activity and induces a dormant phenotype","volume":"129","author":"Chatterjee","year":"2011","journal-title":"Int J Cancer"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2020.265991","article-title":"Early detection of T-cell lymphoma with T follicular helper phenotype by RHOA mutation analysis","volume":"107","author":"Dobson","year":"2022","journal-title":"Haematologica"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110695","article-title":"Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma","volume":"39","author":"Cortes","year":"2022","journal-title":"Cell Rep"},{"key":"B109","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s40164-021-00200-x","article-title":"Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas","volume":"10","author":"Ye","year":"2021","journal-title":"Exp Hematol Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1163190\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,28]],"date-time":"2023-04-28T05:51:43Z","timestamp":1682661103000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2023.1163190\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,28]]},"references-count":109,"alternative-id":["10.3389\/fonc.2023.1163190"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2023.1163190","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,28]]},"article-number":"1163190"}}